SHINE has received a conditional commitment for a loan of $263 million from the U.S. Department of Energy’s (DOE) Office of Energy Dominance Financing, the company announced today.

According to a release, if approved, the financing will support the completion of Chrysalis, the medical isotope production facility that will establish the first domestic commercial supply of molybdenum-99 (Mo-99).

“Chrysalis proves that fusion doesn’t need to wait for future breakthroughs to create value for millions of people today,” SHINE CEO and Founder Greg Piefer said in a statement. “This conditional commitment is a critical catalyst that accelerates our scale-up of the world’s largest medical isotope facility and ensures a secure, domestic source of critical medical isotopes. We are incredibly grateful to the Department of Energy’s rigorous due diligence process and look forward to working to meet the conditions to move forward on the loan.”

SHINE, along with DOE, must satisfy certain technical, legal, environmental and financial conditions before the Department enters into definitive financing documents and funds the loan.